oalib

Publish in OALib Journal

ISSN: 2333-9721

APC: Only $99

Submit

Search Results: 1 - 10 of 251 matches for " inhaled corticosteroid "
All listed articles are free for downloading (OA Articles)
Page 1 /251
Display every page Item
Recurrent pulmonary embolism in a boy with antiphospholipid syndrome  [PDF]
Christian Müller, Christian Willaschek, Mathias Borst, Reiner Buchhorn
Case Reports in Clinical Medicine (CRCM) , 2013, DOI: 10.4236/crcm.2013.25083
Abstract: We report a 14-year-old patient with recurrent pulmonary embolism due to catastrophic antiphospholipid syndrome (APS) with severe pulmonary inflammation. We considered elevated antibodies against cardiolipin and anti-beta2-glycoprotein-1, but no clinical nor laboratory manifestations of systemic lupus erythematosus (SLE). Pulmonary embolism had been the first manifestation of catastrophic APS in this patient. We prescribed warfarin and systemic corticosteroids. A second embolism appeared during anticoagulation with warfarin. This event led to a marked decrease of his physical performance due to his obstructive and restrictive lung disease. Anticoagulation was changed from enteral warfarin to subcutaneous enoxaparine. We also prescribed inhaled corticosteroid which led to an improvement of his respiratory symptoms and overall poor physical condition.
Inhaled budesonide for adults with mild-to-moderate asthma: a randomized placebo-controlled, double-blind clinical trial
Fernandes, Ana Luisa Godoy;Faresin, Sonia Maria;Amorim, Maria Marta;Fritscher, Carlos Cézar;Pereira, Carlos Alberto de Castro;Jardim, José Roberto;
Sao Paulo Medical Journal , 2001, DOI: 10.1590/S1516-31802001000500004
Abstract: context: budesonide is an inhaled corticosteroid with high topical potency and low systemic activity recommended in the treatment of chronic asthma. objective: this study was conducted to determine the efficacy and safety of inhaled budesonide via a breath-activated, multi-dose, dry-powder inhaler. type of study: multicenter randomized parallel-group, placebo-controlled, double-blind, clinical trial. setting: multicenter study in the university units. participants: adult patients with mild-to-moderate asthma that was not controlled using bronchodilator therapy alone. procedures: comparison of budesonide 400 μg administered twice daily via a breath-activated, multi-dose, dry-powder inhaler with placebo, in 43 adult patients (aged 15 to 78 years) with mild-to-moderate asthma (fev1 71% of predicted normal) that was not controlled using bronchodilator therapy alone. main measurements: efficacy was assessed by pulmonary function tests and asthma symptom control (as perceived by the patients) and the use of rescue medication. results: budesonide 400 μg (bid) was significantly more effective than placebo in improving morning peak expiratory flow (mean difference: 67.9 l/min; p < 0.005) and fev1 (mean difference: 0.60 l; p < 0.005) over the 8-week treatment period. onset of action, assessed by morning peak expiratory flow, occurred within the first two weeks of treatment. conclusions: budesonide via a breath-activated, multi-dose, dry-powder inhaler results in a rapid onset of asthma control, which is maintained over time and is well tolerated in adults with mild-to-moderate asthma.
Ciclesonide: a safe and effective inhaled corticosteroid for the treatment of asthma
Timothy J Schaffner, David P Skoner
Journal of Asthma and Allergy , 2009, DOI: http://dx.doi.org/10.2147/JAA.S4651
Abstract: lesonide: a safe and effective inhaled corticosteroid for the treatment of asthma Review (5990) Total Article Views Authors: Timothy J Schaffner, David P Skoner Published Date February 2009 Volume 2009:2 Pages 25 - 32 DOI: http://dx.doi.org/10.2147/JAA.S4651 Timothy J Schaffner1,2 David P Skoner1,2,3 1Division of Allergy, Asthma, and Immunology, Allegheny General Hospital, Pittsburgh, PA, USA; 2West Virginia University School of Medicine, Morgantown, WV, USA; 3Drexel College of Medicine, Philadelphia, PA, USA Abstract: Ciclesonide is a novel inhaled corticosteroid used in the continuous treatment of mild-to-severe asthma. Its formulation and mechanism of action yield a low oral and systemic bioavailability, and high pulmonary deposition. In multiple clinical trials, ciclesonide is at least as effective as either fluticasone propionate or budesonide at symptom control, while in many cases having improved safety outcomes and tolerability. The improved safety and comparable efficacy profiles of ciclesonide demonstrated in current studies could potentially yield a treatment option that may lead to improved adherence and outcome.
Ades?o ao uso de corticóide inalatório na asma: taxas relatadas pelos responsáveis e mensuradas pela farmácia
Lasmar, Laura M. L. B. F.;Camargos, Paulo A. M.;Costa, Leila F.;Fonseca, Maria Teresa M.;Fontes, Maria Jussara F.;Ibiapina, Cassio C.;Alvim, Cristina G.;Moura, José A. R.;Goulart, Eugenio M. A.;Sakurai, Emilia;
Jornal de Pediatria , 2007, DOI: 10.1590/S0021-75572007000600013
Abstract: objective: there is elevated morbidity associated with asthma, particularly in developing countries, and failure to comply with inhaled corticosteroid treatment contributes to this morbidity. the objective of this study is to compare rates of compliance with beclomethasone treatment reported by parents or guardians with those measured by pharmacy dispensing records. methods: a concurrent cohort study of 12 months' duration was carried out, enrolling 106 asthmatic children and adolescents, selected at random. linear regression was used to compare rates of compliance reported by parents or guardians with the pharmacy dispensing records at the service, every 4 months after enrollment on the study. results: compliance rates reported by parents and/or guardians were always higher (p < 0.001) and exhibited a weak correlation with pharmacy records during the period studied; fourth (r = 0.37) and twelfth (r = 0.31) months of follow-up. conclusions: the rates of compliance reported by parents were overestimated during all study periods. the compliance rates of children with asthma should also be monitored by other methods and, in this case, pharmacy records effectively revealed compliance failures. given its low cost, this method is indicated for verification of these compliance rates.
Efficacy and safety characteristics of mometasone furoate/formoterol fumarate fixed-dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52-week placebo-controlled trials
Tashkin DP, Doherty DE, Kerwin E, Matiz-Bueno CE, Knorr B, Shekar T, Gates D, Staudinger H
International Journal of Chronic Obstructive Pulmonary Disease , 2012, DOI: http://dx.doi.org/10.2147/COPD.S29444
Abstract: acy and safety characteristics of mometasone furoate/formoterol fumarate fixed-dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52-week placebo-controlled trials Original Research (4096) Total Article Views Authors: Tashkin DP, Doherty DE, Kerwin E, Matiz-Bueno CE, Knorr B, Shekar T, Gates D, Staudinger H Published Date February 2012 Volume 2012:7 Pages 73 - 86 DOI: http://dx.doi.org/10.2147/COPD.S29444 Received: 24 December 2011 Accepted: 19 January 2012 Published: 03 February 2012 Donald P Tashkin1, Dennis E Doherty2, Edward Kerwin3, Carlos E Matiz-Bueno4, Barbara Knorr5, Tulin Shekar5, Davis Gates5, Heribert Staudinger5 1David Geffen School of Medicine at UCLA, Los Angeles, CA, 2Division of Pulmonary, Critical Care, and Sleep Medicine, University of Kentucky, Lexington, KY, 3Clinical Research Institute of Southern Oregon, Medford, OR, USA; 4Fundación Salud Bosque, Bogota, Colombia, 5Merck Sharp & Dohme Corp, Whitehouse Station, NJ, USA Background: The clinical efficacy and safety of a mometasone furoate/formoterol fumarate (MF/F) fixed-dose combination formulation administered via a metered-dose inhaler was investigated in patients with moderate to very severe chronic obstructive pulmonary disease (COPD). Methods: Two 52-week, multicenter, double-blind, placebo-controlled trials with identical study designs were conducted in current or ex-smokers (aged ≥40 years), and pooled study results are presented herein. Subjects (n = 2251) were randomized to 26 weeks of twice-daily treatment with MF/F 400/10 μg, MF/F 200/10 μg, MF 400 μg, F 10 μg, or placebo. After the 26-week treatment period, placebo subjects completed the trial and 75% of subjects on active treatment entered a 26-week safety extension. Coprimary efficacy variables were mean changes in forced expiratory volume in one second (FEV1), area under the curve from 0 to 12 hours postdose (AUC0–12 h), and morning predose/trough FEV1 from baseline to the week 13 endpoint. Key secondary efficacy variables were St George’s Respiratory Questionnaire scores, symptom-free nights, time-to-first exacerbation, and partly stable COPD at the week 26 endpoint. Results: In the 26-week treatment period, significantly greater increases in FEV1 AUC0–12 h occurred with MF/F 400/10 versus MF 400 and placebo at the week 13 and week 26 endpoints (P ≤ 0.032). These increases were over three-fold greater with MF/F 400/10 than with MF 400. Also, significantly greater increases in morning predose/trough FEV1 occurred with MF/F 400/10 versus F 10 and placebo at the week 13 endpoint (P < 0.05). The increase was four-fold greater with MF/F 400/10 than with F 10. All active treatment groups achieved minimum clinically important differences from baseline (>4 units) in St George’s Respiratory Questionnaire scores at week 26. Symptom-free nights increased by ≥14% in the MF/F 400/10, MF 400, and F 10 groups (P ≤ 0.033 versus placebo). The incidence of exacerbati
Sputum eosinophilia can predict responsiveness to inhaled corticosteroid treatment in patients with overlap syndrome of COPD and asthma
Kitaguchi Y, Komatsu Y, Fujimoto K, Hanaoka M, Kubo K
International Journal of Chronic Obstructive Pulmonary Disease , 2012, DOI: http://dx.doi.org/10.2147/COPD.S30651
Abstract: tum eosinophilia can predict responsiveness to inhaled corticosteroid treatment in patients with overlap syndrome of COPD and asthma Original Research (2906) Total Article Views Authors: Kitaguchi Y, Komatsu Y, Fujimoto K, Hanaoka M, Kubo K Published Date April 2012 Volume 2012:7 Pages 283 - 289 DOI: http://dx.doi.org/10.2147/COPD.S30651 Received: 07 February 2012 Accepted: 14 March 2012 Published: 12 April 2012 Yoshiaki Kitaguchi1,*, Yoshimichi Komatsu1,*, Keisaku Fujimoto2, Masayuki Hanaoka1, Keishi Kubo1 1First Department of Internal Medicine, Shinshu University School of Medicine, 2Department of Biomedical Laboratory Sciences, Shinshu University School of Health Sciences, Matsumoto, Japan *These authors contributed equally to this work Background: Chronic obstructive pulmonary disease (COPD) and asthma may overlap and converge in older people (overlap syndrome). It was hypothesized that patients with overlap syndrome may have different clinical characteristics such as sputum eosinophilia, and better responsiveness to treatment with inhaled corticosteroid (ICS). Methods: Sixty-three patients with stable COPD (forced expiratory volume in 1 second [FEV1] ≤80%) underwent pulmonary function tests, including reversibility of airflow limitation, arterial blood gas analysis, analysis of inflammatory cells in induced sputum, and chest high-resolution computed tomography. The inclusion criteria for COPD patients with asthmatic symptoms included having asthmatic symptoms such as episodic breathlessness, wheezing, cough, and chest tightness worsening at night or in the early morning (COPD with asthma group). The clinical features of COPD patients with asthmatic symptoms were compared with those of COPD patients without asthmatic symptoms (COPD without asthma group). Results: The increases in FEV1 in response to treatment with ICS were significantly higher in the COPD with asthma group. The peripheral eosinophil counts and sputum eosinophil counts were significantly higher. The prevalence of patients with bronchial wall thickening on chest high-resolution computed tomography was significantly higher. A significant correlation was observed between the increases in FEV1 in response to treatment with ICS and sputum eosinophil counts, and between the increases in FEV1 in response to treatment with ICS and the grade of bronchial wall thickening. Receiver operating characteristic curve analysis revealed 82.4% sensitivity and 84.8% specificity of sputum eosinophil count for detecting COPD with asthma, using 2.5% as the cutoff value. Conclusion: COPD patients with asthmatic symptoms had some clinical features. ICS should be considered earlier as a potential treatment in such patients. High sputum eosinophil counts and bronchial wall thickening on chest high-resolution computed tomography might therefore be a good predictor of response to ICS.
Fluticasone furoate: once-daily evening treatment versus twice-daily treatment in moderate asthma
Ashley Woodcock, Eugene R Bleecker, William W Busse, Jan L?tvall, Neil G Snowise, Lucy Frith, Loretta Jacques, Brett Haumann, Eric D Bateman
Respiratory Research , 2011, DOI: 10.1186/1465-9921-12-160
Abstract: Patients with moderate asthma (age ≥ 12 years; pre-bronchodilator forced expiratory volume in 1 second (FEV1) 40-85% predicted; FEV1 reversibility of ≥ 12% and ≥ 200 ml) were randomized to FF or fluticasone propionate (FP) regimens in a double-blind, crossover study. Patients were not permitted to have used any ICS for ≥ 8 weeks prior to enrolment and subsequently received doses of FF or FP 200 μg OD, FF or FP 100 μg BD and matching placebo by inhalation for 28 days each. Primary endpoint was Day 28 evening pre-dose (trough) FEV1; non-inferiority of FF 200 μg OD and FF 100 μg BD was assessed, as was superiority of all active treatment relative to placebo. Adverse events (AEs) and 24-hour urinary cortisol excretion were assessed.The intent-to-treat population comprised 147 (FF) and 43 (FP) patients. On Day 28, pre-dose FEV1 showed FF 200 μg OD to be non-inferior (pre-defined limit -110 ml) to FF 100 μg BD (mean treatment difference 11 ml; 95% CI: -35 to +56 ml); all FF and FP regimens were significantly superior to placebo (p ≤ 0.02). AEs were similar to placebo; no serious AEs were reported. Urinary cortisol excretion at Day 28 for FF was lower than placebo (ratios: 200 μg OD, 0.75; 100 μg BD, 0.84; p ≤ 0.02).FF 200 μg OD in the evening is an efficacious and well tolerated treatment for asthma patients and is not inferior to the same total BD dose.Clinicaltrials.gov; NCT00766090.A variety of treatments are available for asthma but there remains potential to improve the level of disease control in adults and children [1-4]. Failure to achieve asthma control affects patients' daily lives, for example through persistent symptoms, more frequent exacerbations and missed work and school time, placing demands on emergency care facilities [2,5]. Further improvements to the range of therapeutic options for asthma are needed so that patients can achieve better disease control.Inhaled corticosteroids (ICS) are the most effective controller medications for the first-line treatm
Current trends in the treatment of asthma: focus on the simultaneous administration of salmeterol/fluticasone
Robyn Teply, Jennifer Campbell, Daniel Hilleman
Journal of Asthma and Allergy , 2010, DOI: http://dx.doi.org/10.2147/JAA.S6356
Abstract: rrent trends in the treatment of asthma: focus on the simultaneous administration of salmeterol/fluticasone Review (6874) Total Article Views Authors: Robyn Teply, Jennifer Campbell, Daniel Hilleman Published Date March 2010 Volume 2010:3 Pages 1 - 8 DOI: http://dx.doi.org/10.2147/JAA.S6356 Robyn Teply1, Jennifer Campbell2, Daniel Hilleman1 1Creighton University School of Pharmacy and Health Professions, Omaha, NE, USA; 2Creighton Cardiac Center, Omaha, NE, USA Abstract: Asthma is a chronic disease of the airways that affects over 20 million people in the United States. It is a complex disease that involves airway infiltration by different types of cells and cell mediators causing chronic inflammation of the airway as well as hyper-responsiveness and edema. Management of asthma symptoms often requires combination therapy with multiple medications. Long-acting beta-2 agonists and inhaled corticosteroids have become key medications in the prevention of asthma exacerbations. The bronchodilatory effects of the beta-2 agonists coupled with the anti-inflammatory action of the corticosteroids combat the multifactorial causes of asthma. The combination inhaler containing salmeterol and fluticasone is one such product that has been proven safe and effective for asthma therapy.
Effects of mometasone furoate/formoterol fumarate fixed-dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52-week Phase III trial in subjects with moderate-to-very severe COPD
Doherty DE, Tashkin DP, Kerwin E, Knorr BA, Shekar T, Banerjee S, Staudinger H
International Journal of Chronic Obstructive Pulmonary Disease , 2012, DOI: http://dx.doi.org/10.2147/COPD.S27320
Abstract: ts of mometasone furoate/formoterol fumarate fixed-dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52-week Phase III trial in subjects with moderate-to-very severe COPD Original Research (3583) Total Article Views Authors: Doherty DE, Tashkin DP, Kerwin E, Knorr BA, Shekar T, Banerjee S, Staudinger H Published Date February 2012 Volume 2012:7 Pages 57 - 71 DOI: http://dx.doi.org/10.2147/COPD.S27320 Received: 13 October 2011 Accepted: 12 January 2012 Published: 03 February 2012 Dennis E Doherty1, Donald P Tashkin2, Edward Kerwin3, Barbara A Knorr4, Tulin Shekar4, Sibabrata Banerjee4, Heribert Staudinger4 1Division of Pulmonary, Critical Care, and Sleep Medicine, University of Kentucky, Lexington, KY, 2David Geffen School of Medicine at UCLA, Los Angeles, CA, 3Clinical Research Institute of Southern Oregon, Medford, OR, 4Merck Sharp & Dohme Corp, Whitehouse Station, NJ, USA Rationale: The purpose of this study was to investigate the clinical efficacy and safety of a fixed-dose combination of mometasone furoate/formoterol fumarate (MF/F) administered via a metered-dose inhaler in subjects with moderate-to-very severe chronic obstructive pulmonary disease (COPD). Methods: This multicenter, double-blind, placebo-controlled trial had a 26-week treatment period and a 26-week safety extension. Subjects (n = 1196), at least 40 years old, were current or ex-smokers randomized to twice-daily inhaled MF/F 400/10 μg, MF/F 200/10 μg, MF 400 μg, F 10 μg, or placebo. The trial’s co-primary endpoints were mean changes from baseline, as area under the curve (AUC), in forced expiratory volume (FEV1) over 0–12 hours (AUC0-12 h FEV1) with MF/F versus MF, and in morning (AM) pre-dose (trough) FEV1 with MF/F versus F after 13 weeks of treatment. Key secondary endpoints were the effects of MF/F on respiratory health status using the Saint George’s Respiratory Questionnaire (SGRQ), symptom-free nights, partly stable COPD at 26 weeks, and time to first COPD exacerbation. Results: The largest improvements in AUC0-12 h FEV1 were observed with MF/F 400/10 μg and MF/F 200/10 μg. Serial spirometry results demonstrated that bronchodilator effects with MF/F occurred rapidly (within 5 minutes), persisted for 12 hours after dosing, and were sustained over the 26-week treatment period. Similar findings were observed for AM pre-dose FEV1, for which effects were further investigated, excluding subjects whose AM FEV1 data were incorrectly collected after 2 days from the last dose of study treatment. Improvements in SGRQ scores surpassed the minimum clinically important difference of more than four units with both MF/F treatments. At 26 weeks, no notable between-treatment differences in the occurrence and nature of adverse events (AEs) were reported. No unexpected AEs were observed. Overall, 90 subjects reported AEs considered to be treatment-related, the most common of which were lenticular opacities, dysphonia, and oral candidiasis. Discus
Efficacy Evaluation of Different Treatment Regimens with Fluticasone Propionate in Mild Persistent Asthma
Bilan Nemat,M. Shoaran,Asvadi Atabak
Research Journal of Biological Sciences , 2008,
Abstract: Asthma is a chronic airway disorder and prevalence of asthma symptoms in children is about 1-30% and is increasing in many countries. Inhaled Corticosteroids (ICS) are one of the basic therapeutic agents for asthma and their daily frequency is one of the most important factors in the patient adherence to therapy. This study was designed to compare the effect of different frequencies of Fluticasone Propionate on the treatment of mild persistent asthma. This study is a randomized clinical trial on 100 patients with mild persistent asthma at the age of 2-14 years-old receiving Fluticasone Propionate 1 puff twice daily for first 3 months and then 2 puffs once daily for next 3 months are compared to 150 asthmatic patients with the same age range and severity of disease but receiving 1 puff twice daily for 6 months. There was no significant meaningful difference in therapeutic effects of Fluticasone Propionate between two studied groups but adherence to therapy was better in once-daily administered group. Considering the lack of significant difference between two groups and increased parental adherence in first group, the lower frequencies of spray administration after a partial improvement is suggested.
Page 1 /251
Display every page Item


Home
Copyright © 2008-2017 Open Access Library. All rights reserved.